Clinical trials: Essential Hypertension.
Hypertension
A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension
A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HCP1803 in patients with essential hypertension
- Trial name
- HM_APOLLO (NCT05362110)
- Testing
- HCP1803-3, RLD2002, HPP2003-3
- Where
- South Korea
- Volunteers
- 361 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Type 2 Diabetes Mellitus, Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2"
The objective of this clinical study is to evaluate the pharmacokinetics and the safety after administration of "BR1019" and co-administration of "BR1019-1" and "BR1019-2" in healthy volunteers
- Trial name
- NCT06226727
- Testing
- BR1019, BR1019-1, BR1019-2
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
Bioimpedance Evaluation of Therapeutic Titration in Essential, Refractory Hypertension
To determine whether impedance cardiography (ICG) parameters can predict favorable or unfavorable blood pressure (BP) response and time to BP control prior to initiation or intensification of specific antihypertensive drug…
- Trial name
- BETTER-HTN (NCT00913094)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- CardioDynamics
Hypertension
Efficacy/Safety of Valsartan Plus Amlodipine and Valsartan Alone in Patients With Hypertension
This study evaluated the safety and efficacy of the fixed combination of valsartan/amlodipine in adult patients with mild to moderate hypertension.
- Trial name
- NCT00413413
- Testing
- Valsartan/amlodipine 80/5 mg, Valsartan 80 mg, Valsartan 160 mg
- Where
- 19 sites in China
- Volunteers
- 1,134 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333)
To evaluate the blood pressure efficacy between losartan and valsartan at equivalent dosage during a 3 months treatment.
- Trial name
- EASE (NCT00546754)
- Testing
- losartan potassium (+) hydrochlorothiazide, Comparator: Valsartan (+) Hydrochlorothiazide
- Volunteers
- 808 people
- Sponsor
- Organon and Co
Hypertension
Calcium Channel Blockers (CCBs) or Diuretics as an Add-on to Olmesartan Medoxomil in Hypertension
The purpose of the study is to test the efficacy and safety of the combination of Calcium Channel Blockers (CCBs)(of the dihydropyridine class) or Diuretics (of the thiazide class) and olmesartan medoxomil in essential…
- Trial name
- NCT00858702
- Testing
- olmesartan medoxomil and a CCB, olmesartan medoxomil and a diuretic
- Where
- Japan
- Volunteers
- 105 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Hypertension, Isolated Systolic Hypertension (ISH)
A Single Rising Dose Study of MK-8150 (MK-8150-001)
This study will evaluate the safety and tolerability of MK-8150 and its effect on central systolic blood pressure (cSBP) and heart rate corrected augmentation index (AIx) when given as single oral doses in healthy males and in…
- Trial name
- NCT01590810
- Testing
- MK-8150 2.0 mg, MK-8150 10 mg, MK-8150 40 mg
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension
Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)
The purpose of this study is to assess the efficacy, safety, and tolerability of 8 weeks of therapy with nebivolol in comparison to placebo in younger patients 18 - 54 years of age with stage 1 or stage 2 essential hypertension.
- Trial name
- NCT01415531
- Testing
- Nebivolol
- Where
- 75 sites in United States
- Volunteers
- 641 people
- Sponsor
- Forest Laboratories
Hypertension
Long Term Study Of Amlodipine 10mg With Hypertension For Whom Amlodipine 5mg Is Insufficient
To investigate the safety and efficacy of the long-term use of amlodipine 10 mg in subjects who will be able to enter a long-term study after completing the parent study "A double-blind comparative study between amlodipine 5 mg…
- Trial name
- NCT00443456
- Testing
- Amlodipine
- Where
- 9 sites in Japan
- Volunteers
- 134 people
- Sponsor
- Pfizer
Essential Hypertension
A Study to Evaluate the Effect of Fimasartan on Pharmacokinetics, and the Safety of Digoxin in Healthy Male Volunteers
The purpose of this study is to evaluate the effect of fimasartan on pharmacokinetics, and the safety of digoxin.
- Trial name
- NCT00991783
- Testing
- Digoxin + Fimasartan
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension, Hypertension,Essential
Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension
This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ADX-850 in participants with hypertension.
- Trial name
- NCT06205628
- Testing
- ADX-850
- Where
- 3 sites in Australia
- Volunteers
- 28 people
- Sponsor
- ADARx Pharmaceuticals, Inc.
Arterial Hypertension
Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control
The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.
- Trial name
- NCT02483936
- Testing
- Olmesartan medoxomil 40mg + chlorthalidone 12,5mg, Olmesartan medoxomil 40mg + chlorthalidone 25mg, Olmesartan 40mg + Hydrochlorothiazide 12,5mg
- Sponsor
- EMS
Essential Hypertension
Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide
The CoCa study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e.
- Trial name
- CoCa (NCT00608153)
- Volunteers
- 1,773 people
- Sponsor
- AstraZeneca
Essential Hypertension
A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension
A Multi-center, Randomized, Double-blind, Parallel design, Phase III study to Evaluate and Compare the Efficacy and Safety of DWC202405/DWC202313 and DWC202314 Combination Therapy to DWC202405/DWC202313 in Patients with Essential…
- Trial name
- NCT06671392
- Testing
- DWC202405, DWC202405, DWC202314, DWC202405, DWC202314P
- Where
- South Korea
- Volunteers
- 198 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Hypertension
A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension
A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HCP1803 compared to RLD2001-1 in patients with essential hypertension
- Trial name
- HM_APOLLO (NCT06438172)
- Testing
- HCP1803-3, RLD2001-1, HPP2003-3
- Where
- South Korea
- Volunteers
- 249 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Essential Hypertension
Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study
This is a national multicenter, prospective, observational study. It is planned to enroll 1215 patients with newly diagnosed essential hypertension in 80 centers, and divide them into 3 groups according to different treatment…
- Trial name
- NCT05947448
- Testing
- Azilsartan Medoxomil Potassium Tablet, Nifedipine Sustained -release Tablets, Levoamlodipine Maleate Table
- Where
- China
- Volunteers
- 1,215 people
- Sponsor
- Hasten Biopharmaceutical Co., Ltd.
Hypertension
A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)
This study is being conducted to evaluate the safety of MK-0954A (L100/H12.5 mg) in essential hypertension participants who are uncontrolled with MK-954H (L50/H12.5 mg).
- Trial name
- NCT01307033
- Testing
- MK-0954A, MK-954H
- Volunteers
- 278 people
- Sponsor
- Organon and Co
Essential Hypertension
Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Central Arterial Pressure
The purpose of this study is to compare nifedipine controlled-release (CR) tablets (Xin Ran) with nifedipine controlled-release tablets (Adalat）in the treatment of Early Morning Blood Pressure and Central Arterial Pressure.
- Trial name
- NCT02357615
- Testing
- nifedipine CR tablets (Xin Ran), Adalat
- Where
- China
- Volunteers
- 244 people
- Sponsor
- Shanghai Shyndec Pharmaceutical Co., Ltd.
Essential Hypertension, Atherosclerotic Cardiovascular Disease
Olmesartan Medoxomil in Atherosclerosis
This is a study in hypertensive patients with atherosclerosis and increased cardiovascular risk. The efficacy of olmesartan medoxomil on atherosclerosis is measured.
- Trial name
- NCT00185185
- Testing
- Olmesartan medoxomil, Atenolol, Hydrochlorothiazide
- Where
- Germany
- Volunteers
- 165 people
- Sponsor
- Sankyo Pharma Gmbh
Essential Hypertension
Efficacy of Rostafuroxin in the Treatment of Essential Hypertension
The purpose of this study is to verify the efficacy of Rostafuroxin in the treatment of essential hypertension and to determine the best effective dose to be administered in the general hypertensive population and in a subset of…
- Trial name
- NCT00415038
- Testing
- Rostafuroxin
- Where
- Belgium
- Volunteers
- 438 people
- Sponsor
- sigma-tau i.f.r. S.p.A.